GlassScriptPhysician profile
Peter Maanao
NPI 1154026425
$1,656.23
in general payments reported to CMS, 2019-2025
23 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $163 · 2024: $388 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $344.33 | 2025 | |
| Neurocrine Biosciences, INC. | $243.88 | 2024-2025 | Ingrezza |
| Pfizer INC. | $213.10 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.95 | 2023-2025 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $84.54 | 2025 | Austedo Xr, Ajovy |
| Alexion Pharmaceuticals, INC. | $73.55 | 2023-2025 | Ultomiris |
| Biotronik Nro, INC. | $65.80 | 2023 | Biotronik |
| Forte Bio-Pharma LLC | $61.61 | 2024 | Prolate, Nalocet |
| Amgen INC. | $53.95 | 2025 | Uplizna |
| Argenx US, INC. | $53.20 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $49.60 | 2024 | Vyepti |
| Scilex Pharmaceuticals INC. | $47.79 | 2023-2024 | Ztlido |
| Si-Bone, INC. | $44.59 | 2023-2024 | |
| Genentech USA, INC. | $42.11 | 2024-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Merz Pharmaceuticals, LLC | $29.79 | 2024 | Xeomin |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $29.30 | 2024 | Mild Device Kit |
| Neurelis, INC. | $24.62 | 2024 | Valtoco |
| Appliedvr INC | $21.80 | 2025 | Relievrx |
| Philips North America LLC | $20.89 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Otsuka America Pharmaceutical, INC. | $16.47 | 2025 | Rexulti |
| Painteq LLC | $16.20 | 2024 | Painteq |
| Spr Therapeutics, INC | $14.82 | 2024 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.34 | 2025 | Relistor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Maanao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.